This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Bryophyllum vs. Nifedipine

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2006 by Weleda AG.
Recruitment status was:  Not yet recruiting
Sponsor:
Information provided by:
Weleda AG
ClinicalTrials.gov Identifier:
NCT00391339
First received: October 19, 2006
Last updated: NA
Last verified: October 2006
History: No changes posted
  Purpose
In a prospective, randomised study the efficacy and tolerability of bryophyllum p. (p.o) vs. nifedipine (p.o) will be proofed in a defined group of pregnant women with threatened preterm labour.

Condition Intervention Phase
Tocolysis Drug: Bryophyllum p. Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Bryophyllum p. Versus Nifedipine for the Treatment of Premature Contractions

Resource links provided by NLM:


Further study details as provided by Weleda AG:

Estimated Enrollment: 140
Study Start Date: November 2006
Estimated Study Completion Date: October 2008
  Eligibility

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Female

Exclusion Criteria:

  • Bishop Score > 5
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00391339

Locations
Switzerland
Department of Obstetrics, University of Zuerich Not yet recruiting
Zuerich, Switzerland, 8091
Principal Investigator: Roland Zimmermann, Prof. Dr. med.         
Principal Investigator: Ursula von Mandach, Prof. Dr. pharm.         
Sponsors and Collaborators
Weleda AG
Investigators
Principal Investigator: Roland Zimmermann, Prof. Dr. med. Department of Obstetrics, University Zuerich
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00391339     History of Changes
Other Study ID Numbers: CI-C-64-Wel-06
Study First Received: October 19, 2006
Last Updated: October 19, 2006

Keywords provided by Weleda AG:
Bryophyllum p.
Nifedipine
Tocolysis

Additional relevant MeSH terms:
Nifedipine
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Tocolytic Agents
Reproductive Control Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 26, 2017